

Fig. 6. Preventive effect of catalase-expressing Ad vectors on CCl_4 -induced acute liver failure. CCl_4 (1 ml/kg) was intraperitoneally injected to mice 48 h following Ad vector injection. Serum samples were collected 24 h after CCl_4 administration. The data are expressed as the means \pm S.D. ($n = 4$). *Significantly different from the PBS-injected group at $p < 0.05$; ** at $p < 0.01$.

3.5. Improvement of survival rates of mice subjected to partial hepatectomy and hepatic ischemia/reperfusion by catalase-expressing Ad vectors

To examine whether over-expression of catalase improves the remnant liver function in mice subjected to both partial hepatectomy and I/R treatment, partial hepatectomy and subsequent I/R treatment were conducted 48 h after pre-administration of Ad vectors. Partial hepatectomy is often performed under hepatic ischemia, and the remaining liver suffers from I/R injury after partial hepatectomy in clinical settings. Mice pre-administered with AdK7-CAT showed a dramatic improvement in survival rate (Fig. 7). Seventy percent of mice survived for 7 days after these treatments. The body weights of the mice pre-injected with AdK7-CAT were not significantly reduced 7 days after surgery, compared with those before surgery (data not shown), suggesting that the general health of the mice was not substantially compromised after the surgery. On the other hand, the survival of the mice was not prolonged by pre-administration of Ad-LacZ or PBS. These results indicate that catalase-expressing Ad vectors are able to protect the liver from more serious stress induced by partial hepatectomy and I/R, and to improve the remnant liver function.

4. Discussion

Hepatotoxins, drugs, and I/R can injure the liver via oxidative stress. With the aim of efficiently preventing oxidative stress-induced hepatic




Fig. 7. Survival rates of mice subjected to partial hepatectomy and hepatic I/R following Ad vector administration. Solid line: PBS ($n = 5$); dotted line: AdK7-LacZ ($n = 7$); dashed line: AdK7-CAT ($n = 11$). Ad vectors were intravenously administered to mice as described in Fig. 4. Forty-eight hours after Ad vector administration, mice were subjected to two-thirds partial hepatectomy, followed by an 8 min-period of ischemia

injury, we pre-administered Ad vectors expressing an antioxidative enzyme, catalase, to mice. The results of our study demonstrated that Ad vector-mediated over-expression of catalase in the liver effectively prevents hepatic injury caused by not only I/R but also CCl_4 . Furthermore, the survival rates of mice subjected to both partial hepatectomy and I/R treatment were prolonged by over-expression of catalase.

Superoxide anion is the primary oxidant species generated during hepatic I/R by a xanthine oxidase system and/or decoupling of the electron transport system in mitochondria. Superoxide anion is readily converted to H_2O_2 by SOD or a spontaneous reaction. H_2O_2 itself is a weak oxidizing agent; however, hydroxyl radical is produced by H_2O_2 in the presence of transition-metal ion. Hydroxyl radical has the most oxidative ability and the strongest toxicity among the various ROS. Reduction/elimination of hydroxyl radical is considered to be the most effective strategy for prevention of hepatic I/R injury. Therefore, catalase, which prevents generation of hydroxyl radical by converting H_2O_2 to H_2O and O_2 , was selected as the antioxidant enzyme in the present study. Catalase derivatives also exhibited higher preventive effects on the elevation of serum ALT and AST levels induced by hepatic I/R, compared with SOD derivatives [5,6]. In addition, over-expression of catalase in the liver might increase endogenous expression of SOD, which is another advantage of catalase gene transfer. He et al. demonstrated that delivery of catalase gene alone to the liver induced SOD activity in the liver [17].

Partial hepatectomy is often performed under hepatic ischemia. Previous studies have shown that oxidative stress induced by hepatic I/R affects hepatocyte cell death and inhibits liver regeneration [42,43]. Beyer et al. reported that ROS are directly responsible for the impairment of insulin/insulin-like growth factor 1 signaling, which is crucial for liver regeneration [44]. Furthermore, hepatocytes without catalase activity have been found in regenerating livers after partial hepatectomy [45], suggesting that hepatocytes in the regenerating livers might be susceptible for ROS-mediated injury. The present study demonstrated that over-expression of catalase in the liver dramatically improved the survival rates of mice subjected to partial hepatectomy and I/R, suggesting that the remnant livers would be protected from ROS-mediated injury by over-expression of catalase. Furthermore, over-expression of catalase might play an important role in maintenance of the regenerative capacity of hepatocytes. Recently, removal of ROS by antioxidant enzymes was demonstrated to be crucial for maintenance of the self-renewal capacity of progenitor/stem cells in an *in vitro* culture system [46,47]. In this study, the liver/body weight ratio of mice pre-injected with AdK7-CAT 1 week after partial hepatectomy and I/R was $4.7 \pm 0.55\%$, which is not significantly different from that of naïve mice (data not shown).

Oxidative stress is also generated in the liver through metabolism of a variety of drugs, chemicals, and toxins, such as thioacetamide, lipopolysaccharide, and CCl_4 . In particular, CCl_4 is often used as a representative hepatotoxin causing oxidative stress in animal experiments. CCl_4 is metabolized by cytochrome P450 in the endoplasmic reticulum of hepatocytes, leading to generation of CCl_3 radical, which induces hepatic damages, although the mechanism of CCl_4 -mediated liver damage has not yet been fully revealed. The present study showed that Ad vector-mediated over-expression of catalase in the liver also attenuated CCl_4 -induced liver injury (Fig. 6). Over-expression of SOD has also been shown to inhibit CCl_4 -induced hepatic damages [48]. Hepatic delivery of genes encoding ROS-deleting enzymes is effective in case of hepatic injury induced by oxidative stress-generating hepatotoxins and chemical compounds.

Ad vectors offer various advantages for gene delivery to the liver; however, systemic administration of Ad vectors often induces inflammatory cytokine production and hepatic damage [24,49–51]. However, we found no apparent Ad vector-induced damages in the liver in this study (data not shown). Moreover, mice pre-administered Ad-LacZ or AdK7-LacZ did not exhibit higher levels of serum ALT and AST after I/R than those pre-administered PBS (Fig. 4). This was likely

due to the relatively low dose of Ad vectors (1×10^{10} VP/mouse) used in this study. Higher doses of Ad vectors have often been administered in the studies reporting Ad vector-mediated *in vivo* toxicities [49,51]. We confirmed that more than 90% of hepatocytes were efficiently transduced even at a dose of 1×10^{10} VP/mouse in this study (data not shown). In general, Ad vectors have been considered more toxic than non-viral vectors containing plasmid DNA; however, our group recently revealed that Ad vectors induced smaller amounts of inflammatory cytokines, which are partly involved in Ad vector-induced hepatic toxicity, following intravenous administration into mice, compared with plasmid DNA/cationic liposome complexes, which were used as a representative of non-viral gene delivery vehicle [23]. In both that previous study and our present work, Ad vectors successfully deliver antioxidant genes to the liver with no apparent toxicity, although we should pay attention to the vector doses.

In addition to conventional Ad vectors, fiber-modified AdK7 vectors, which display a poly-lysine motif on the c-terminal of the fiber knob, [24,35,52] were used in this study. AdK7 vectors mediate not only significantly higher transgene expression in the liver but also lower *in vivo* damages than conventional Ad vectors [24]. However, the serum ALT and AST levels of the mice receiving Ad-CAT and AdK7-CAT were not significantly different from those of the controls in this study (Fig. 4), although histological analysis of the liver sections revealed that AdK7-CAT conferred superior protection against I/R injury (Fig. 5), probably because sufficient levels of catalase would be expressed by Ad-CAT at this dose to prevent hepatic I/R-induced increases in serum ALT and AST in this setting. AdK7-CAT might show higher protective effects than conventional Ad vectors under more severe conditions.

In conclusion, the present study demonstrated that Ad vector-mediated catalase expression in the liver significantly improved I/R-induced hepatic injury. These findings suggest that Ad vectors expressing antioxidant enzymes would contribute to the development of strategies aimed at inhibiting hepatic I/R injury. Antioxidant enzyme-expressing Ad vectors are also applicable for the prevention of I/R-induced injury in other organs and oxidative stress-induced damages caused by ROS-generating chemicals. Moreover, their combined use with other antioxidant genes or anti-apoptosis genes could further attenuate oxidative stress-induced injury.

Acknowledgement

We thank Dr. Yuriko Higuchi (Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan) for her help in the liver ischemia/reperfusion experiments. We also thank Dr. Kazuo Ohashi (Institute of Advanced Biomedical Engineering and Sciences, Tokyo Women's Medical University, Tokyo, Japan) for his help in the partial hepatectomy experiment. This work was supported by grants from the Ministry of Health, Labour, and Welfare of Japan.

References

- [1] R.G. Thurman, et al., Hepatic reperfusion injury following orthotopic liver transplantation in the rat, *Transplantation* 46 (1988) 502–506.
- [2] J.M. McCord, Oxygen-derived free radicals in postschemic tissue injury. *N. Engl. J. Med.* 312 (1985) 159–163.
- [3] M.J. Arthur, et al., Oxygen-derived free radicals promote hepatic injury in the rat. *Gastroenterology* 89 (1985) 1114–1122.
- [4] D.N. Granger, R.J. Korhuis, Physiologic mechanisms of postschemic tissue injury. *Annu. Rev. Physiol.* 57 (1995) 311–332.
- [5] Y. Yabe, et al., Prevention of neutrophil-mediated hepatic ischemia/reperfusion injury by superoxide dismutase and catalase derivatives. *J. Pharmacol. Exp. Ther.* 298 (2001) 894–899.
- [6] Y. Yabe, et al., Targeted delivery and improved therapeutic potential of catalase by chemical modification: combination with superoxide dismutase derivatives. *J. Pharmacol. Exp. Ther.* 289 (1999) 1176–1184.
- [7] S.L. Atala, L.H. Toledo-Pereyra, G.H. MacKenzie, J.P. Cederna, Influence of oxygen-derived free radical scavengers on ischemic livers. *Transplantation* 40 (1985) 594–599.

- [8] T. Fujita, et al., Therapeutic effects of superoxide dismutase derivatives modified with mono- or polysaccharides on hepatic injury induced by ischemia/reperfusion. *Biochem. Biophys. Res. Commun.* 189 (1992) 191–196.
- [9] P.S. Pyatak, A. Abuchowski, F.F. Davis, Preparation of a polyethylene glycol: superoxide dismutase adduct, and an examination of its blood circulation life and anti-inflammatory activity. *Res. Commun. Chem. Pathol. Pharmacol.* 29 (1980) 113–127.
- [10] J.F. Turrens, J.D. Crapo, B.A. Freeman, Protection against oxygen toxicity by intravenous injection of liposome-entrapped catalase and superoxide dismutase. *J. Clin. Invest.* 73 (1984) 87–95.
- [11] L. Agrawal, et al., Antioxidant enzyme gene delivery to protect from HIV-1 gp120-induced neuronal apoptosis. *Gene Ther.* 13 (2006) 1645–1656.
- [12] P.Y. Benhamou, et al., Adenovirus-mediated catalase gene transfer reduces oxidant stress in human, porcine and rat pancreatic islets. *Diabetologia* 41 (1998) 1093–1100.
- [13] E. Durand, et al., Adenovirus-mediated gene transfer of superoxide dismutase and catalase decreases restenosis after balloon angioplasty. *J. Vasc. Res.* 42 (2005) 255–265.
- [14] F. Sakurai, H. Mizuguchi, T. Yamaguchi, T. Hayakawa, Characterization of *in vitro* and *in vivo* gene transfer properties of adenovirus serotype 35 vector. *Mol. Ther.* 8 (2003) 813–821.
- [15] H. Mizuguchi, et al., CAR- or alpha integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice. *Gene Ther.* 9 (2002) 769–776.
- [16] R. Alemany, D.T. Curiel, CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. *Gene Ther.* 8 (2001) 1347–1353.
- [17] S.J. He, et al., Delivery of antioxidant enzyme genes protects against ischemia/reperfusion-induced liver injury in mice. *Liver Transpl.* 12 (2006) 1869–1879.
- [18] H. Yin, et al., Pretreatment with soluble ST2 reduces warm hepatic ischemia/reperfusion injury. *Biochem. Biophys. Res. Commun.* 351 (2006) 940–946.
- [19] R.S. Sung, L. Qin, J.S. Bromberg, TNFalpha and IFNgamma induced by innate anti-adenoviral immune responses inhibit adenovirus-mediated transgene expression. *Mol. Ther.* 3 (2001) 757–767.
- [20] N. Morral, et al., Immune responses to reporter proteins and high viral dose limit durability of gene transfer with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. *Hum. Gene Ther.* 8 (1997) 1275–1286.
- [21] S. Li, L. Huang, *In vivo* gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. *Gene Ther.* 4 (1997) 891–900.
- [22] S. Li, et al., Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors. *Am. J. Physiol.* 276 (1999) L796–L804.
- [23] H. Sakurai, et al., Comparison of gene expression efficiency and innate immune response induced by Ad vector and lipopolyplex. *J. Control. Release* 117 (2007) 430–437.
- [24] N. Koizumi, et al., Fiber-modified adenovirus vectors decrease liver toxicity through reduced IL-6 production. *J. Immunol.* 178 (2007) 1767–1773.
- [25] M.D. Wheeler, et al., Comparison of the effect of adenoviral delivery of three superoxide dismutase genes against hepatic ischemia–reperfusion injury. *Hum. Gene Ther.* 12 (2001) 2167–2177.
- [26] S. Kondo, et al., Mannosylated superoxide dismutase inhibits hepatic reperfusion injury in rats. *J. Surg. Res.* 60 (1996) 36–40.
- [27] B. Chen, et al., Delivery of antioxidant enzyme genes protects against ischemia/reperfusion-induced injury to retinal microvasculature. *Invest. Ophthalmol. Vis. Sci.* 50 (2009) 5587–5595.
- [28] H. Mizuguchi, M.A. Kay, Efficient construction of a recombinant adenovirus vector by an improved *in vitro* ligation method. *Hum. Gene Ther.* 9 (1998) 2577–2583.
- [29] H. Mizuguchi, M.A. Kay, A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. *Hum. Gene Ther.* 10 (1999) 2013–2017.
- [30] H. Mizuguchi, et al., A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. *Gene Ther.* 8 (2001) 730–735.
- [31] M. Mari, J. Bai, A.I. Cederbaum, Adenovirus-mediated overexpression of catalase in the cytosolic or mitochondrial compartment protects against toxicity caused by glutathione depletion in HepG2 cells expressing CYP2E1. *J. Pharmacol. Exp. Ther.* 301 (2002) 111–118.
- [32] J. Bai, A.I. Cederbaum, Adenovirus-mediated overexpression of catalase in the cytosolic or mitochondrial compartment protects against cytochrome P450 2E1-dependent toxicity in HepG2 cells. *J. Biol. Chem.* 276 (2001) 4315–4321.
- [33] F. Sakurai, et al., Optimization of adenovirus serotype 35 vectors for efficient transduction in human hematopoietic progenitors: comparison of promoter activities. *Gene Ther.* 12 (2005) 1424–1433.
- [34] J.V. Maizel Jr., D.O. White, M.D. Schaffir, The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. *Virology* 36 (1968) 115–125.
- [35] N. Koizumi, et al., Generation of fiber-modified adenovirus vectors containing heterologous peptides in both the HI loop and C terminus of the fiber knob. *J. Gene Med.* 5 (2003) 267–276.
- [36] A. Tsung, et al., The nuclear factor HMG1B1 mediates hepatic injury after murine liver ischemia–reperfusion. *J. Exp. Med.* 201 (2005) 1135–1143.
- [37] M.R. Duranski, et al., Cytoprotective effects of nitrite during *in vivo* ischemia–reperfusion of the heart and liver. *J. Clin. Invest.* 115 (2005) 1232–1240.
- [38] K. Ohashi, F. Park, M.A. Kay, Role of hepatocyte direct hyperplasia in lentivirus-mediated liver transduction *in vivo*. *Hum. Gene Ther.* 13 (2002) 653–663.
- [39] K. Ohashi, et al., Liver tissue engineering at extrahepatic sites in mice as a potential new therapy for genetic liver diseases. *Hepatology* 41 (2005) 132–140.
- [40] T.J. Monks, et al., Quinone chemistry and toxicity. *Toxicol. Appl. Pharmacol.* 112 (1992) 2–16.
- [41] H. Tori, et al., The metabolism of menadiol (2-methyl-, 1,4-naphthoquinone) by isolated hepatocytes. A study of the implications of oxidative stress in intact cells. *J. Biol. Chem.* 257 (1982) 12419–12425.
- [42] N. Fausto, Liver regeneration. *J. Hepatol.* 32 (2000) 19–31.

- [43] H. Kamata, et al., Reactive oxygen species promote TNF α -induced death and sustained JNK activation by inhibiting MAP kinase phosphatases, *Cell* 120 (2005) 649–661.
- [44] T.A. Beyer, et al., Impaired liver regeneration in Nrf2 knockout mice: role of ROS-mediated insulin/IGF-1 resistance, *Embo J.* 27 (2008) 212–223.
- [45] I. Oikawa, P.M. Novikoff, Catalase-negative peroxisomes: transient appearance in rat hepatocytes during liver regeneration after partial hepatectomy, *Am. J. Pathol.* 146 (1995) 673–687.
- [46] R.C. Meagher, A.J. Salvado, D.G. Wright, An analysis of the multilineage production of human hematopoietic progenitors in long-term bone marrow culture: evidence that reactive oxygen intermediates derived from mature phagocytic cells have a role in limiting progenitor cell self-renewal, *Blood* 72 (1988) 273–281.
- [47] R. Gupta, S. Karparkin, R.S. Basch, Hematopoiesis and stem cell renewal in long-term bone marrow cultures containing catalase, *Blood* 107 (2006) 1837–1846.
- [48] S.K. Venugopal, et al., Lentivirus-mediated superoxide dismutase1 gene delivery protects against oxidative stress-induced liver injury in mice, *Liver Int.* 27 (2007) 1311–1322.
- [49] M. Christ, et al., Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products, *Hum. Gene Ther.* 11 (2000) 415–427.
- [50] A. Lieber, et al., Inhibition of NF- κ B activation in combination with bcl-2 expression allows for persistence of first-generation adenovirus vectors in the mouse liver, *J. Virol.* 72 (1998) 9267–9277.
- [51] R.S. Everett, et al., Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors, *Hum. Gene Ther.* 14 (2003) 1715–1726.
- [52] T.J. Wickham, et al., increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins, *J. virol.* 71 (1997) 8221–8229.

Potency of Claudin-targeting as Antitumor Therapy

Rie Saeki¹, Masuo Kondoh¹, Hiroshi Uchida² and Kiyohito Yagi¹

¹Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan; ²Department of Biopharmaceuticals Research, Biopharma Center, Asubio Pharma Co., Ltd., Gunma 370-0503, Japan

PharmSight on Saeki R et al., A novel tumor-targeted therapy using a claudin-4-targeting molecule. *Mol Pharmacol* 2009;76:918-26.

Abstract

Approximately 90% of malignant tumors are derived from the epithelium. Epithelium has well-developed tight junctions (TJs), which become deregulated and disrupted during epithelial transformation. Claudin-4, a pivotal functional and structural component of TJs, is often overexpressed in human cancers. In the present study, we prepared a claudin-4 binder, the C-terminal fragment of *Clostridium perfringens* enterotoxin (C-CPE), fused to a cytotoxic molecule (C-CPE-PSIF) and found that C-CPE-PSIF is toxic to claudin-4-expressing cells. Interestingly, C-CPE-PSIF was less toxic in polarized than depolarized cells, and treatment of polarized cells with C-CPE-PSIF from the basal but not apical side was cytotoxic. C-CPE-PSIF also exhibits antitumor activity. C-CPE mutants with alanine substitutions were more cytotoxic than C-CPE. These findings indicate that the claudin-4 binder, C-CPE, is a potent lead molecule for the development of claudin-targeted tumor therapy.

Keywords: Claudin; *Clostridium perfringens* enterotoxin; *Pseudomonas* exotoxin; Anti-tumor activity

Introduction

Tight junctions (TJs) consist of three main classes of proteins: claudins, occludin, and junctional adhesion molecules. Claudins regulate the integrity

and function of TJs (1). The human family of claudin proteins contains at least 23 members, and their expression profiles and functions are tissue and cell specific (2). Changes in claudin expression occur in malignant tumors, and the expression profiles differ among tissues (3, 4). For example, claudin-1 and -10 are overexpressed in colon and hepatocellular cancer cells, respectively (3), while claudin-4 is up-regulated in breast, ovarian, pancreatic, colorectal, hepatic and bladder cancers (Table 1). Thus, claudins are potential targets for tumor therapy. However, claudin has low antigenicity, and it is difficult to generate antibodies to the extracellular region of claudins.

Clostridium perfringens enterotoxin (CPE) is a single polypeptide of 35 kDa that causes food poisoning in humans. The functional domains of CPE are classified into the N-terminal cytotoxic and C-terminal receptor-binding regions (5, 6). Two years after the CPE receptor was identified in 1997, it was found to be identical to claudin-4 (7, 8). Interestingly, C-terminal CPE, which corresponds to amino acids 184 to 319 (C-CPE₁₈₄₋₃₁₉), binds to claudin-4 and inhibits TJ function. We previously found that C-CPE₁₈₄₋₃₁₉ is a useful ligand for claudin-4 (9). However, C-CPE₁₈₄₋₃₁₉ has poor solubility (0.3 mg/ml) and is difficult to use in pharmaceutical therapy. In 2008, Van Itallie et al. showed that a slightly smaller polypeptide, C-CPE₁₉₄₋₃₁₉, has high solubility (>10 mg/ml) and high affinity to claudin-4 (10).

Pseudomonas aeruginosa exotoxin A (PE) is widely used in cancer-targeting study (11). PE binds to the cell surface and is internalized via endocytosis; then, a PE fragment, protein synthesis inhibitory factor (PSIF), escapes from the endosome to the cytosol (12), where it inhibits protein synthesis by inhibiting elongation factor 2. PSIF lacks the receptor-binding domain of PE, and fusion of a tumor

Received 11/25/09; accepted 02/24/10

Correspondence: Dr. Masuo Kondoh, Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871, Japan. Tel. 81-6-6879-8196, Fax. 81-6-6879-8199, e-mail: masuo@phs.osaka-u.ac.jp; Dr. Kiyohito Yagi, Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871, Japan. Tel. 81-6-6879-8195, Fax. 81-6-6879-8195, e-mail: yagi@phs.osaka-u.ac.jp

Table 1 Changes in expression of claudin-4 in cancer cells

Cancer	Expression	References
Prostate	Up	(25)
Breast	Up	(26, 27)
Ovarian	Up	(28-31)
Pancreatic	Up	(32-34)
Colorectal	Up	(35)
Uterus	UP	(36, 37)
Gastric	Down	(38, 39)
Hepatocellular	Up	(40)

antigen ligand with PSIF is a promising strategy for cancer-targeting therapy.

In the present study, we genetically prepared a claudin-4-targeting molecule (C-CPE₁₉₄₋₃₁₉-PSIF) containing the claudin-4-binding region of CPE and PSIF (Figure 1A). We also investigated whether C-CPE₁₉₄₋₃₁₉ (referred to as C-CPE hereafter) is useful for claudin-4-targeted cancer therapy.

Results and Discussion

L cells, which are a mouse fibroblast cell line, do not express any claudins. Therefore, we investigated the cytotoxicity of C-CPE-PSIF in claudin-4-expressing L cells (CL4/L cells). C-CPE-PSIF caused dose-dependent cytotoxicity in CL4/L cells, reaching >90% cell death at 10 ng/ml. In contrast, even at 20 ng/ml, PSIF was not cytotoxic to CL4/L cells (13). C-CPE-PSIF showed specific toxicity in CL4/L cells, and pretreatment of the cells with C-CPE attenuated the C-CPE-PSIF-induced cytotoxicity, indicating that C-CPE-PSIF may interact with claudin-4 via its C-CPE domain (13).

Claudin-4 is expressed in tissues including the lung, intestine, liver, and kidney. Most claudins in normal cells are contained in TJ complexes, whereas the localization of claudin is deregulated in some cancers. C-CPE-PSIF may recognize the deregulated localization of claudin-4. Confluent Caco-2 cells form a polarized cell monolayer with well-developed TJs, and they are frequently used as a model of polarized cells. Confluent Caco-2 cells express more claudin-4 than pre-confluent cells; however, C-CPE-PSIF was more toxic in the pre-confluent cells with fewer TJs

(47% cell death at 5 ng/ml) than in the confluent cells with well-developed TJs (40% cell death, even at 200 ng/ml) (13).

Early events in epithelial carcinogenesis are deregulation of cellular polarity and loss of TJ structures. We examined whether the sensitivity of cells to C-CPE-PSIF is affected by their cellular polarity using Caco-2 monolayer cell sheets grown on the membrane in Transwell chambers. The Caco-2 monolayer cells exhibit a well-differentiated brush border containing TJs on the apical surface, and they are frequently used as an epithelial cell sheet model. After the addition of C-CPE-PSIF to the apical or basolateral compartment of the Transwell chamber, we assessed the TJ barrier function of the cell sheets by measuring transepithelial electric resistance (TER). When C-CPE-PSIF was added to the apical compartment, TER was not affected for 48 h. In contrast, the addition of C-CPE-PSIF to the basolateral compartment caused a significant and dose-dependent reduction in TER. Furthermore, the addition of C-CPE-PSIF to the basolateral compartment, but not the apical compartment, increased the amount of released lactate dehydrogenase, a marker of cytotoxicity (13). These results indicate that C-CPE-PSIF has specific effects based on the cellular density and polarity.

We examined the antitumor activity of C-CPE-PSIF in 4T1 cells, a mouse breast cancer cell line that expresses claudin-4. To clarify the antitumor activity of the claudin-4-targeting molecule (C-CPE-PSIF), we prepared a fusion protein of PSIF with mutant C-CPE, in which Tyr306 and Leu315 (critical residues for the interaction between C-CPE

and claudin-4) were changed to alanines, resulting in C-CPE^{Y306A/L315A}-PSIF (14). C-CPE-PSIF mediated dose-dependent cytotoxicity in 4T1 cells, reaching 63% cell death at 100 ng/ml. In contrast, C-CPE^{Y306A/L315A}-PSIF was not cytotoxic even at 500 ng/ml, indicating that the cytotoxicity of C-CPE-PSIF in 4T1 cells may be mediated by its binding to claudin-4. To investigate the *in vivo* antitumor activity of C-CPE-PSIF, 4T1 cells (2×10^6 cells) were inoculated into the right flank of mice on day 0. Vehicle, C-CPE, C-CPE-PSIF or C-CPE^{Y306A/L315A}-PSIF at a dose of 5 μ g/kg was intratumorally injected on days 2, 4, 7, 9, 11, and 14. C-CPE-PSIF significantly suppressed tumor growth, and the tumor volume in the C-CPE-PSIF-treated group was 36% of that in the vehicle-treated group on day 16. In contrast, C-CPE and C-CPE^{Y306A/L315A}-PSIF, which lacked claudin-4-binding activity, had no effect on tumor growth, indicating that the antitumor activity of C-CPE-PSIF may depend on claudin-4 targeting (13).

We previously investigated the functional domains of C-CPE and found that the 16 C-terminal amino acids of C-CPE are involved in claudin-4 binding; we also found that the claudin-4 affinities of the N309A mutant, which contains Ala instead of Asn at position 309, and the S313A mutant, which contains Ala instead of Ser at position 313, were greater than that of C-CPE (14, 15). To improve the claudin-4-targeting molecule, we prepared C-CPE^{S313A}-PSIF and C-CPE^{N309A/S313A}-PSIF (Figure 1A). C-CPE^{S313A}-PSIF and C-CPE^{N309A/S313A}-PSIF were more cytotoxic than C-CPE-PSIF in CL4/L cells (Figure 1B). We are currently investigating the antitumor activity of these mutants and developing other C-CPE mutant-PSIF constructs with greater cytotoxicity. To develop novel methods of tumor diagnosis and therapies that target the initial stage of malignant transformation, we are also developing novel claudins binders, in addition to optimizing C-CPE, the conventional claudin-binder.

Perspective of claudin-targeted tumor therapy

Approximately 7.6 million people worldwide die from cancer each year, and 90% of malignant tumors are derived from epithelial tissues (16) (<http://www.reuters.com/article/healthNews/idUSN1633064920071217>).

Cancer cells grow slowly during the very early stage of malignant transformation, after which they grow exponentially and form tumor tissues. Tumors that reach a mass of 10^{12} cancer cells lead to death.




Figure 1. Cytotoxicity of C-CPE-PSIF fusion proteins (A) Schematic illustration of C-CPE-PSIF fusion proteins. C-CPE is the C-terminal fragment of CPE corresponding to amino acids 194-319. The dark area indicates the putative claudin-4-binding region (15). Changing Asn to Ala at position of 309 of Ser to Ala at position of 313 improved the affinity of C-CPE to claudin-4 (14). C-CPE^{S313A} or C-CPE^{N309A/S313A}-fused PSIF was also prepared. PSIF contains domain II (the critical domain for the escape of the toxin from the endosome to the cytosol) and domain III (the critical domain for the inhibition of protein synthesis) of *Pseudomonas* exotoxin. (B) Cytotoxicity of C-CPE-PSIF. CL4/L cells were treated with the C-CPE-PSIF fusion proteins at the indicated concentration for 24 h. The cellular viability was measured by a WST-8 assay kit, according to the manufacturer's instructions (Nacal Tesque, Kyoto, Japan). Viability (%) was calculated as a percentage of the vehicle-treated cells. The data represent the mean \pm SD of three independent experiments.

Diagnosable cancer tumors contain at least 10^9 cells, and tumors with 10^9 - 10^{12} cells are subject to cancer therapy. An important goal in cancer therapy is improving the ability to detect tumors containing less than 10^9 cells so that they can be more successfully treated.

Epithelial tissues are characterized by specific cellular polarity. The establishment and maintenance of cell polarity involve many processes, including signaling cascades, membrane trafficking events and cytoskeletal dynamics, and relies on the apical junctional system, TJs (17, 18). TJs seal the intercellular space between adjacent cells and regulate the solute movement across epithelial

sheets. TJs between neighboring cells allow the separation of apical and basolateral membrane domains that vary in protein and lipid contents, resulting in the maintenance of cell polarity and the regulation of cellular proliferation (19). An important hallmark of malignant transformation is loss of epithelial polarity (20).

In normal polarized epithelial cells, the mitotic spindles are parallel to the epithelial planar axis, and cellular proliferation is regulated by intercellular contact. Cell-cell adhesion provides a cortical planar cue to orient the mitotic spindle parallel to the epithelial plane (21-23). In an early stage of epithelial tumorigenesis, the orientation of mitotic spindles becomes deregulated, resulting in out-of-plane division (24) (Figure 2). Cell division is controlled by cytoskeletal dynamics (i.e., the mitotic spindle, actin filaments and microtubules), and cell-cell adhesions and their associated molecules are thought to be connected to the cytoskeletal organization and partly control these cytoskeletal elements (22). Thus, misorientation of the cell division axis might cause changes in the function and localization of the cell-cell adhesion system.

Despite the lateral localization of TJs and their components in normal epithelial cell sheets, TJs and their components might be exposed on the cellular surface by the rotation of spindles, indicating that TJ components might be a therapeutic target during the early stage of epithelial tumorigenesis. Our goal is to develop a novel tumor-targeting therapy using the TJ components that are exposed to the apical membrane from the lateral membrane by rotation of the mitotic axis.

Acknowledgements

We thank Drs S. Tsunoda (National Institute of Biomedical Innovation, Osaka, Japan) and Y. Horiguchi (Osaka University, Osaka, Japan) for providing us PSIF cDNA and C-CPE cDNA, respectively. We also thank the members of our laboratory for their useful comments and discussion. This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan (21689006), by a Health and Labor Sciences Research Grants from the Ministry of Health, Labor and Welfare of Japan, by Takeda Science Foundation, by a Suzuken Memorial Foundation and by a grant from Kansai Biomedical Cluster project in Saito, which is promoted by the Knowledge Cluster Initiative of the Ministry of Education, Culture, Sports, Science and Technology, Japan.




Figure 2. Scheme of malignant transformation in epithelium. In normal epithelial cells, the cells are divided in parallel with the epithelial plane. In the early stage of epithelial tumorigenesis, the orientation of the mitotic spindles is deregulated, and the cells proliferate by out-of-plane division (24).

Conflicts of Interest

No potential conflicts of interest to disclose.

References

1. Tsukita S, Furuse M. Occludin and claudins in tight-junction strands: leading or supporting players? *Trends Cell Biol* 1999;9:268-73.
2. Furuse M, Tsukita S. Claudins in occluding junctions of humans and flies. *Trends Cell Biol* 2006;16:181-8.
3. Morin PJ. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. *Cancer Res* 2005;65:9603-6.
4. Swisshelm K, Macek R, Kubbies M. Role of claudins in tumorigenesis. *Adv Drug Deliv Rev* 2005;57:919-28.
5. Hanna PC, Wiekowski EU, Mietzner TA, McClane B A. Mapping of functional regions of *Clostridium perfringens* type A enterotoxin. *Infect Immun* 1992;60:2110-4.
6. McClane BA, Chakrabarti G. New insights into the cytotoxic mechanisms of *Clostridium perfringens* enterotoxin. *Anaerobe* 2004;10:107-14.
7. Katahira J, Inoue N, Horiguchi Y, Matsuda M, Sugimoto N. Molecular cloning and functional characterization of the receptor for *Clostridium perfringens* enterotoxin. *J Cell Biol* 1997;136:1239-47.
8. Sonoda N, Furuse M, Sasaki H, et al. *Clostridium perfringens* enterotoxin fragment removes specific claudins from tight junction strands: Evidence for direct involvement of claudins in tight junction barrier. *J Cell Biol* 1999;147:195-204.
9. Ebihara C, Kondoh M, Hasuike N, et al. Preparation of a claudin-targeting molecule using a C-terminal fragment of *Clostridium perfringens* enterotoxin. *J Pharmacol Exp Ther* 2006;316:255-60.

10. Van Itallie CM, Betts L, Smedley JG3rd, McClane BA, Anderson JM. Structure of the claudin-binding domain of *Clostridium perfringens* enterotoxin. *J Biol Chem* 2008;283:268-74.
11. Kreitman RJ, Pastan I. Immunotoxins in the treatment of hematologic malignancies. *Curr Drug Targets* 2006;7:1301-11.
12. Kreitman RJ. Immunotoxins in cancer therapy. *Curr Opin Immunol* 1999;11:570-8.
13. Saeki R, Kondoh M, Kakutani H, et al. A novel tumor-targeted therapy using a claudin-4-targeting molecule. *Mol Pharmacol* 2009;76:918-26.
14. Takahashi A, Komiya E, Kakutani H, et al. Domain mapping of a claudin-4 modulator, the C-terminal region of C-terminal fragment of *Clostridium perfringens* enterotoxin, by site-directed mutagenesis. *Biochem Pharmacol* 2008;76:1639-48.
15. Takahashi A, Kondoh M, Masuyama A, et al. Role of C-terminal regions of the C-terminal fragment of *Clostridium perfringens* enterotoxin in its interaction with claudin-4. *J Control Release* 2005;108:56-62.
16. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. *CA Cancer J Clin* 2008;58:71-96.
17. Matter K, Aijaz S, Tsapara A, Balda MS. Mammalian tight junctions in the regulation of epithelial differentiation and proliferation. *Curr Opin Cell Biol* 2005;17:453-8.
18. Matter K, Balda MS. Functional analysis of tight junctions. *Methods* 2003;30:228-34.
19. Vermeer PD, Einwalter LA, Moninger TO, et al. Segregation of receptor and ligand regulates activation of epithelial growth factor receptor. *Nature* 2003;422:322-6.
20. Wodarz A, Nathke I. Cell polarity in development and cancer. *Nat Cell Biol* 2007;9:1016-24.
21. Lu B, Roegiers F, Jan LY, Jan YN. Adherens junctions inhibit asymmetric division in the *Drosophila* epithelium. *Nature* 2001;409:522-5.
22. Reinsch S, Karsenti E. Orientation of spindle axis and distribution of plasma membrane proteins during cell division in polarized MDCKII cells. *J Cell Biol* 1994;126:1509-26.
23. Toyoshima F, Matsumura S, Morimoto H, Mitsuhashi M, Nishida E. PtdIns(3,4,5)P₃ regulates spindle orientation in adherent cells. *Dev Cell* 2007;13:796-811.
24. Beamish H, de Boer L, Giles N, et al. Cyclin A/cdk2 regulates adenomatous polyposis coli-dependent mitotic spindle anchoring. *J Biol Chem* 2009;284:29015-23.
25. Long H, Crean CD, Lee WH, Cummings OW, Gabig TG. Expression of *Clostridium perfringens* enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. *Cancer Res* 2001;61:7878-81.
26. Kominsky SL, Vali M, Korz D, et al. *Clostridium perfringens* enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. *Am J Pathol* 2004;164:1627-33.
27. Tokes AM, Kulka J, Paku S, et al. Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. *Breast Cancer Res* 2005;7:R296-305.
28. Hibbs K, Skubitz KM, Pambuccian SE, et al. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. *Am J Pathol* 2004;165:397-414.
29. Hough CD, Sherman-Baust CA, Pizer ES, et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. *Cancer Res* 2000;60:6281-7.
30. Rangel LB, Agarwal R, D'Souza T, et al. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. *Clin Cancer Res* 2003;9:2567-75.
31. Santin AD, Zhan F, Bellone S, et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. *Int J Cancer* 2004;112:14-25.
32. Gress TM, Muller-Pillasch F, Geng M, et al. A pancreatic cancer-specific expression profile. *Oncogene* 1996;13:1819-30.
33. Michl P, Buchholz M, Rolke M, et al. Claudin-4: a new target for pancreatic cancer treatment using *Clostridium perfringens* enterotoxin. *Gastroenterology* 2001;121:678-84.
34. Nichols LS, Ashfaq R, Iacobuzio-Donahue CA. Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. *Am J Clin Pathol* 2004;121:226-30.
35. Mees ST, Mennigen R, Spieker T, et al. Expression of tight and adherens junction proteins in ulcerative colitis associated colorectal carcinoma: upregulation of claudin-1, claudin-3, claudin-4, and beta-catenin. *Int J Colorectal Dis* 2009;24:361-8.
36. Santin AD, Bellone S, Siegel ER, et al. Overexpression of *Clostridium perfringens* enterotoxin receptors claudin-3 and claudin-4 in uterine carcinosarcomas. *Clin Cancer Res* 2007;13:3339-46.
37. Santin AD, Zhan F, Cane S, et al. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. *Br J Cancer* 2005;92:1561-73.
38. Lee SK, Moon J, Park SW, et al. Loss of the tight junction protein claudin 4 correlates with histological growth-pattern and differentiation in advanced gastric adenocarcinoma. *Oncol Rep* 2005;13:193-9.
39. Soini Y, Tommola S, Helin H, Martikainen P. Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype. *Virchows Arch* 2006;448:52-8.
40. Nishino R, Honda M, Yamashita T, et al. Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. *J Hepatol* 2008;49:207-16.

《若手研究者紹介》



生体バリアの分子基盤を利用した創薬研究

近 藤 昌 夫* Masuo Kondoh

大阪大学大学院薬学研究所

1. はじめに

オーストラリアの動物学者ローレンツは、動物の生活史のある特定の時期に特定の物事がごく短時間で覚えこまれその記憶が長期間に渡り持続する学習現象「刷り込み」を見出している。小職の研究における刷り込みは、学部3回生の時に恩師の生物薬理学の講義の中で聞いた「細胞製剤：細胞を敬え、細胞に学べ」という言葉である。本稿では、恩師による刷り込みを経て生体バリアの分子基盤を利用した創薬研究に至るまでの経緯を振り返ってみたい。

入学後テニスに明け暮れていた小職は3回生に進学してから、少しずつ研究室配属を考え始めるようになっていた。小職なりに「未来の薬」について思索してみたものの、キックサーブやトップスピンロブに関する知識では薬学に関するアイデアが思い浮かぶはずもなかった。小職なりに行き詰まりを感じていた矢先、恩師の生物薬理学の講義の中で、「細胞製剤」という言葉を聞き、全身から鳥肌が立つような感動を覚えた。恩師は講義の中で、「自分の置かれた「場所」と「時間」に適合しつつ恒常性を維持している細胞が究極の剤形であること、この細胞から学ぶことにより必要な時に、必要な場所に、必要な量だけ薬を運ぶDDS技術の開発が可能になること」を熱く語られていた。大学院から恩師の研究室に入り、「細胞製剤：細胞を敬い、細胞に学べ」という学

問を徹底的に叩き込まれた。細胞生物学に立脚した薬剤学を志向する研究生活を送る中で、同じサイトカインの刺激であっても細胞によって細胞内シグナル伝達経路が異なり、その結果として刺激に対して相反する反応が惹起される場合もなることを知り、細胞によって顔ばかりでなく細胞内も異なることに非常に興味を惹かれた。その当時の私の知識では、当時の薬剤学は細胞表面の議論に終始しているように思え（後に単なる勉強不足であることが分かったが）、「1）細胞内の物質輸送の様子を見る、2）細胞の時間（細胞周期）を学ぶ、3）細胞内でのシグナル伝達の様子を見る」という3点について基礎力を身に付けた上で最終的に「独自の細胞製剤を開発する」という戦略を立て、博士課程在学中に理化学研究所抗生物質研究室に国内留学し、細胞周期阻害剤に関する研究に従事した。その後、徳島文理大学薬学部において、重金属や酸化的ストレスに対する生体応答反応に関する研究に携わり分子・細胞・個体レベルでの研究実施方法に関する基礎を多くの研究者からご教示頂き、同年代の研究者と「研究のオリジナリティーとは？」というテーマを着に酒席において口泡を飛ばす議論を繰り返した。このときの議論仲間には、医学部、農学部、理学部、工学部など研究文化の異なるモザイク集団であった。振り返ると、この議論が小職の研究哲学をある程度形づくっていたように思う。

そして2002年4月に昭和薬科大学薬剤学教室に移動になったのを機に、独自の創薬研究領域の立ち上げに着手することを決意した。

*平成10年徳島文理大学薬学部助手、平成14年昭和薬科大学講師、平成18年大阪大学大学院薬学研究所助教を経て平成19年4月より同大学准教授。研究テーマ：生体バリアを利用した創薬研究。趣味：テニス、ジョギング、散歩。連絡先：〒565-0871 吹田市山田丘1-6 E-mail: masuo @ phs.osaka-u.ac.jp

2. これまで

独自の創薬研究領域の立ち上げを決意した時に思い浮かんだ言葉が、「細胞を敬え、細胞を学べ」という恩師の教えであった。小職がこの世界に飛び込むきっかけとなったこの言葉を念頭に置き、まず「どの細胞から学ぶか？」ということ考え、①創薬研究において重要な細胞であること、②創薬研究領域において未開拓の分野が残されていること、③活用する細胞生物学的知見が国産であること、④温故知新という基本方針を設定した上で、細胞生物学の教科書を紐解き、上皮細胞に注目することにした。

周知のように上皮細胞は生体内外・組織内外を隔てるバリアとして機能していること、悪性腫瘍の90%が上皮由来であること、多くの病原性微生物の侵入門戸となっていることから、上皮細胞は薬物吸収、癌治療や感染症治療・予防における創薬ターゲットとして有用な性質を有している。上皮細胞を標的とした創薬研究としては、80年代より吸収促進剤が研究開発されているものの、実用化された吸収促進剤はカプリン酸ナトリウムのみであり、非特異的な物質の流入に起因する安全性確保が困難であることから paracellular route を介した薬物吸収促進法の限界が指摘されている部分もあった。上皮細胞生物学の分野では、既に60年代には tight junction (TJ) によって paracellular route がシールされていることが知られていたが、TJ 分子基盤の解明は遅れており、ようやく98年になって TJ シールが膜蛋白質によって構成されていることが証明された。このことは、従来の吸収促進剤の限界は paracellular route を利用した創薬研究の限界を示しているのではなく、上皮細胞生物学の遅延により TJ の分子基盤に立脚した創薬戦略が取られてこなかったことに起因していることを意味していた。そこで小職のグループでは、TJ の分子基盤に立脚した創薬研究領域の開拓を広義の目標として設定し、TJ シールの機能本体でありシール機能に組織特異性を有する分子という条件により標的分子の絞り込みを試み、京大月田グループにより同定されていた claudin に注目した。

Claudin は分子量~23 kDa の4回膜貫通蛋白質であり、24種類の分子からなるファミリーを形成している。興味深いことに発現およびバリア機能には

組織特異性が認められ、claudin-1 は皮膚バリア、claudin-5 は血液脳関門バリアを担っている。さらに、ヒトでは12種類の癌において発現異常が認められること、粘膜免疫組織に高発現していること、ウイルスの感染受容体としても機能していることから、claudin を標的とした薬物吸収促進法、癌ターゲットニング法、粘膜ワクチン、抗ウイルス薬の開発など、新たな創薬研究領域創成の可能性が強く示唆された。しかしながら、claudin は抗原性が低い上に立体構造が解析されておらず、抗体を含めて claudin binder の創製は著しく立ち遅れており、claudin を利用した創薬研究は皆無に等しいのが現状であった。

ウエルシュ菌下痢毒素(CPE)はヒトの食中毒を引き起こすことから細菌学の分野で詳細な解析が進められており、97年にCPE受容体が同定されていたものの、本受容体の生理的役割についての解析は遅々として進展していなかった。99年月田グループにより、CPE受容体が claudin-4 であること、CPEの受容体結合領域断片(C-CPE)が細胞傷害性を伴うことなく claudin-4 に結合し claudin-4 バリア機能を阻害することが報告され、claudin が TJ バリア機能を担っていることが実験的に初めて証明されていた。小職は、徳島文理大在職中にウエルシュ菌研究の世界的権威である櫻井純先生から、細菌毒素の持つ特異性について薫陶を受けていたこともあり、この月田グループの報告を読んだ時に C-CPE を利用することで claudin を標的とした創薬研究を展開できると直感した。さらに、C-CPE はポリペプチドであり将来的な遺伝子工学的手法を用いた改変が容易(C-CPE を prototype として用いた新規 claudin binder の創製が可能)であることから、C-CPE を claudin binder のモデル分子として利用し、claudin を利用した創薬研究に着手することにした。


2002年7月に、C-CPE の遺伝子を持ついる阪大磯研堀口先生に手紙を差し上げ、C-CPE cDNA を譲渡して頂き、試行錯誤しながら C-CPE 蛋白質を作製した。そして、当時修士1年生であった浅野長祥君にお願いし、モデル薬物として分子量4000のデキストラン(FD-4)を用いてラット腸管ループ法により粘膜吸収促進活性を解析してもらった。すると、わずか0.2 mg/ml の処理で劇的な FD-4 の吸収促進活性が観察され、このとき粘膜傷害性は観察さ

れなかった。当時小職は天然物由来の生理活性物質の機能解析および胎盤における亜鉛代謝に関する研究を進めており、claudinを利用した研究はエフォートの10%程度を割いているに過ぎない状況であった。実際、生理活性物質の機能解析については論文1報がアクセプトされ、複数の論文を投稿準備中という状況であり、両研究とも順調に推移していた。そこで、主に下級生を中心にテーマの選択と集中に関して忌憚の無いディスカッションを行い、両研究テーマを切り上げclaudinを利用した創薬研究にチームを挙げて取り組むことを決意した。そして、C-CPEが唯一のclaudin binderであることを踏まえ、①C-CPEをclaudin binderのモデル分子として利用し、claudinを利用した創薬研究の可能性を検証すること、②C-CPEをprototypeとして用いたclaudin binder創製系を構築すること、③新たなclaudin制御分子の探索を試みることをメインテーマとして

設定し、claudinを利用した創薬研究に本格的にアタックすることにした。2002年12月のことである。

まず、C-CPEの粘膜吸収促進活性がclaudin-4を介して生じていることを確認するために、C-CPEのclaudin-4結合ドメインの同定を試み、C-CPEのclaudin-4結合領域欠損体を創出し、本欠損体を用いてclaudinを用いた粘膜吸収促進法の有用性を明らかにした(図1)¹⁾。さらに、C-CPE変異体を用いてclaudinを利用したペプチド医薬の経肺・経鼻吸収促進法を開発した²⁾。また、C-CPEと緑膿菌エキソトキシン由来の蛋白合成阻害因子(PSIF)との融合蛋白質C-CPE-PSIFを作製し、claudin-4発現癌細胞に対する抗腫瘍活性を解析し、C-CPE-PSIFがclaudin-4指向性分子であること、C-CPE-PSIFが*in vitro*および*in vivo*で抗腫瘍活性を有することを見出し、C-CPEを用いた癌ターゲティング法を確立した(図2)^{3,4)}。さらに、2003年に東大医科研の清野グループにより、粘膜免疫組織にclaudin-4が高発現していることが見出され、claudin-4を標的とした粘膜免疫組織への抗原デリバリーの可能性が示唆されていた。そこで、C-CPEとモデル抗原の融合蛋白質を作製し、claudin-4を標的とした粘膜ワクチン創製の可否を検証し、C-CPEとモデル抗原との混合液投与では抗原特異的な免疫応答が観察され

A. 血漿中FD-4濃度の経時変化



B. AUC値




図1 C-CPEの腸管吸収促進活性

FITCラベルした分子量4000のデキストラン(FD-4)をモデル薬物として用いて、ラット腸管ループ法によりC-CPEの吸収促進活性を解析(文献1を一部改変)。

A. C-CPE-PSIF



B. Claudin (CL) 特異性






図2 Claudin-4指向性分子

Pseudomonas aeruginosa exotoxinの蛋白質合成阻害ドメイン(PSIF)とC-CPEとの融合体(A)を作製し、各種claudin発現細胞に各濃度24時間処理後にWSTアッセイにより細胞毒性を解析(B)。


A. OVA-C-CPE



C. 鼻粘膜 抗OVA IgA



B. 血中 抗OVA IgG



D. 糞便中 抗OVA IgA




図3 Claudin binderを利用した粘膜ワクチン

モデル抗原(卵白アルブミン:OVA)とC-CPEとの融合体(A)を作製し、マウスに経鼻投与し、血中(B)、鼻粘膜洗浄液(C)、糞便抽出液(D)に含まれるOVA特異的抗体価を解析。



図4 生体バリアを利用した創薬研究

ないこと、融合蛋白質投与によって投与粘膜面のみならず遠隔粘膜面での抗原特異的IgA産生が起きること、claudin-4結合性が消失したC-CPE変異体との融合蛋白質では抗体価の上昇が観察されないことを見出し、claudin-4を標的とした粘膜ワクチン技術を初めて確立した(図3)⁵⁾。さらに、C-CPEをprototypeとして用いたclaudin binder創製を図るために5年余りの歳月をかけて、C-CPEのclaudin結合残基を網羅的に解析、claudin binderのスクリーニングシステムを構築し、最近新規claudin binderの取得に成功した(Unpublished data)。

以上、現在までの検討により、claudinを標的と

した粘膜吸収促進法、癌ターゲット法、粘膜ワクチン技術を開製し、claudinを利用した創薬の可能性を先駆けて報告してきた。さらに、C-CPEに比して優れた粘膜バリア制御活性を有する新規claudin binderの開製、およびclaudin binder創製系の構築にも成功している。

3. これから

上述したように、現在までにclaudinが開薬ターゲットとして多くの可能性を秘めていることを見出してきた。Claudinは24種類の分子が多様な組み合わせによって様々な性質を有するTJシールを構成し、生体内の多種多様な内部環境を維持していることから、この内部環境維持機構を自由自在に制御することができれば、新たなdrug delivery system(DDS)の開発に繋がる可能性がある。今後は、独自のclaudin binder創製技術を駆使して、多種多様な結合域を有するclaudin binderを開製し、組織特異性および透過物質特異性を併せ持つ新規薬物吸収促進法の開発、新規癌ターゲット法、ウイルス感染阻害剤の開発などの創薬研究を展開していきたい(図4)。

三つ子の魂百までというように、「細胞を敬え、細

胞に学べ」という刷り込みに支配され、上皮細胞および claudin の可能性に魅せられ、現在まで歩んできた。引き続き小職らのグループでは、本邦独自の細胞生物学研究土壌に育まれた本邦独自の創薬領域の開拓、およびその成果の実用化を目指し、激烈にチャレンジを続けていく予定である。

本稿を執筆する機会を与えて頂いた出口芳春先生を始めとした編集委員の先生方に深謝申し上げます。また、本稿でご紹介した研究成果は、大阪大学大学院薬学研究科生体機能分子化学分野八木清仁先生、昭和薬科大学薬剤学研究室渡邊善照先生、藤井まき子先生、アスピオファーマ株式会社内田博司先生をはじめとした多くの先生方のご指導ご鞭撻の所産であり、相互作用頂いた全ての方々衷心よりお礼申し上げます。

また、実際の研究は多くの優秀な学生によって進められております。Claudin を利用した粘膜吸収促進に関する研究は増山西さん、原田東樹君、高橋梓さん、古宮栄利子さんを中心としたグループ、claudin を利用したバイオ医薬の非侵襲性投与方法の開発は山浦利章君、高橋梓さん、松久幸司君、松下恭平君、各務洋平君を中心とした研究グループ、claudin を利用した癌ターゲティング法の開発は海老原千晶さん、佐伯理恵さん、角谷秀樹君を中心とした研究グループ、claudin を利用した粘膜ワクチンの開発は角谷秀樹君、深坂昌弘君、鈴木英彦君を中心とした研究グループ、新規 claudin binder の創製は高橋梓さん、山浦利章君、齋藤郁美子さん、松下恭平君、各務洋平君を中心とした研究グループによって進め

られたものでございます。この場をお借りして相互作用頂いた学生の皆様へ改めてお礼申し上げます。

当該研究成果の一部は、文部科学省科研費、文部科学省知的クラスター創成事業、厚生労働省科研費、武田科学振興財団からのサポートにより実施されたものでございます。 Grant サポートを賜りました関係者の皆様方に深謝申し上げます。

最後に、「細胞製剤」という学問を授けていただいた恩師眞弓忠範先生に衷心よりお礼を申し上げ、拙稿の結びとさせていただきます。

引用文献

- 1) M. Kondoh, A. Masuyama, A. Takahashi, N. Asano, H. Mizuguchi, N. Koizumi, M. Fujii, T. Hayakawa, Y. Horiguchi, A. Watanabe, A novel strategy for the enhancement of drug absorption using a claudin modulator, *Mol. Pharmacol.*, **67**, 749–756 (2005).
- 2) H. Uchida, M. Kondoh, T. Hanada, A. Takahashi, T. Hamakubo, K. Yagi, A claudin-4 modulator enhances the mucosal absorption of a biologically active peptide, *Biochem. Pharmacol.*, **79**, 1437–1444 (2010).
- 3) R. Saeki, M. Kondoh, H. Kakutani, S. Tsunoda, Y. Mochizuki, T. Hamakubo, Y. Tsutsumi, Y. Horiguchi, K. Yagi, A novel tumor-targeting using a claudin-4-targeting molecule, *Mol. Pharmacol.*, **76**, 918–926 (2009).
- 4) R. Saeki, M. Kondoh, H. Kakutani, K. Matsuhisa, A. Takahashi, H. Suzuki, Y. Kakamu, A. Watari, K. Yagi, A claudin-targeting molecule as an inhibitor of tumor metastasis, *J. Pharmacol. Exp. Ther.*, **334**, 576–582 (2010).
- 5) H. Kakutani, M. Kondoh, M. Fukasaka, H. Suzuki, T. Hamakubo, K. Yagi, Mucosal vaccination using claudin-4 targeting, *Biomaterials*, **31**, 5463–5471 (2010).

A Claudin-Targeting Molecule as an Inhibitor of Tumor Metastasis[§]

Rie Saeki, Masuo Kondoh, Hideki Kakutani, Kohji Matsuhisa, Azusa Takahashi, Hidehiko Suzuki, Yohei Kakamu, Akihiro Watari, and Kiyohito Yagi

Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan

Received March 10, 2010; accepted May 3, 2010

ABSTRACT

Tumor metastasis of epithelium-derived tumors is the major cause of death from malignant tumors. Overexpression of claudin is observed frequently in malignant tumors. However, claudin-targeting antimetastasis therapy has never been investigated. We previously prepared a claudin-4-targeting antitumor molecule that consisted of the C-terminal fragment of *Clostridium perfringens* enterotoxin (C-CPE) fused to protein synthesis inhibitory factor (PSIF) derived from *Pseudomonas* exotoxin. In the present study, we investigated whether claudin CPE receptors can be a target for tumor metastasis by using the C-CPE-fused PSIF as a claudin-targeting agent. One of the most popular murine metastasis mod-

els is the lung metastasis of intravenously injected B16 cells. Therefore, we first investigated the effects of the C-CPE-fused PSIF on lung metastasis of claudin-4-expressing B16 (CL4-B16) cells. Intravenous administration of the C-CPE-fused PSIF suppressed lung metastasis of CL4-B16 cells but not B16 cells. Injection of C-CPE-fused PSIF also inhibited tumor growth and spontaneous lung metastasis of murine breast cancer 4T1 cells inoculated into the subcutis. Treatment with C-CPE-fused PSIF did not show apparent side effects in mice. These findings indicate that claudin targeting may be a novel strategy for inhibiting some tumor metastases.

Metastasis is the primary cause of death for most cancer patients (Gupta and Massagué, 2006; Steeg, 2006). Metastasis occurs during tumor growth and even during the surgical excision of the primary tumor. A great deal of effort has been made to overcome tumor metastasis, including the development of several potent methods for irradiation therapy, chemotherapy, and immunotherapy. However, 7 million patients worldwide die from malignant tumors each year, and the majority of malignant tumors are derived from the epithelium (Jemal et al., 2008). Thus, the development of a novel antitumor strategy against epithelium-derived cancer metastasis is needed.

The epithelium is located at the border between the outer and inner body and tissue. Spaces between the adjacent cells in

epithelium are sealed by tight junctions (TJs). TJs prevent free movement of solutes across epithelium through the paracellular spaces and also maintain cellular polarity by regulating the localization of cellular membrane proteins, such as transporters, ion channels, and receptors, between the apical and basal sides of epithelial cells (Mitic and Anderson, 1998; Vermeer et al., 2003). Moreover, TJs control cell proliferation by regulating the localization of receptors on the cellular membrane and the intracellular signal transduction for cellular proliferation and differentiation (Vermeer et al., 2003; Matter et al., 2005). These TJ functions are frequently deregulated during tumorigenesis, and tumor cells often exhibit abnormalities in cellular polarity and differentiation (Martin and Jiang, 2001; Wodarz and Näthke, 2007). The loss of the integrity of the TJ seal in tumors may contribute to the supply of nutrition critical for tumor growth and the detachment of cancer cells from the primary tumor tissues, leading to the malignancy of tumors (Mullin, 1997; Martin and Jiang, 2001).

Freeze-fracture replica microscopy analysis revealed that TJs form a series of continuous strands within plasma membranes (Staehelein, 1973). TJ strands from the membranes of adjacent cells form a paired strand, and the paired strands seal the intercellular space between the adjacent cells. The TJ strands are composed of integral membrane proteins,

This work was supported by the Ministry of Education, Culture, Sports, Science, and Technology, Japan [Grant-in-Aid for Scientific Research 21689006], Health and Labor Sciences research grants from the Ministry of Health, Labor, and Welfare of Japan, the Takeda Science Foundation, and a grant from Kansai Biomedical Cluster Project in Suita, which is promoted by the Knowledge Cluster Initiative of the Ministry of Education, Culture, Sports, Science, and Technology of Japan. H.K. and A.T. are supported by research fellowships from the Japan Society for the Promotion of Science for Young Scientists.

Article, publication date, and citation information can be found at <http://jpet.aspetjournals.org>.

doi:10.1124/jpet.110.168070.

[§]The online version of this article (available at <http://jpet.aspetjournals.org>) contains supplemental material.

ABBREVIATIONS: CPE, *Clostridium perfringens* enterotoxin; C-CPE, C-terminal fragment of CPE; PSIF, protein synthesis inhibitory factor; C-CPE-PSIF, C-CPE-fused PSIF; CL4-B16, claudin-4-expressing B16; TJ, tight junction; FBS, fetal bovine serum; DMEM, Dulbecco's modified Eagle's medium; PBS, phosphate-buffered saline; ADR, adriamycin.

such as occludin and claudin, and among them, claudin is a key structural and functional component of TJ seals (Furuse and Tsukita, 2006). Claudin, a tetra-transmembrane protein, comprises a family consisting of more than 20 members. The expression profiles and sealing functions of claudins differ among tissues. Claudin expression is often deregulated in human cancers such as breast, prostate, ovarian, gastric, and pancreatic cancers (Morin, 2005; Kominsky, 2006). There is a relationship between dysregulated claudin and metastasis (Agarwal et al., 2005; Dhawan et al., 2005). These findings indicate that claudin can be a potent target for cancer therapy.

Clostridium perfringens enterotoxin (CPE), a 35-kDa polypeptide, causes food poisoning in humans. CPE binds to its receptor, and then causes changes in the membrane permeability by complex formation on the plasma membrane followed by the induction of oncosis and apoptosis (McClane and Chakrabarti, 2004). The local administration of CPE suppresses solid tumor growth (Michl et al., 2001; Kominsky et al., 2004; Santin et al., 2005); however, whole CPE had never been applied into a ligand for claudin CPE receptors because of its strong cytotoxicity. The receptor-binding region of CPE (C-CPE) can be used for claudin-targeted cancer therapy (Saeki et al., 2009). Immunotoxins, consisting of a protein toxin connected to a binding ligand, such as an antibody or growth factor, have been developed and used for clinical therapy. Protein synthesis inhibitory factor (PSIF) derived from *Pseudomonas* exotoxin is a widely used protein toxin (Kreitman and Pastan, 2006), and intratumoral administration of the claudin-4-targeting PSIF has been shown to attenuate solid tumor growth (Saeki et al., 2009). In the present study, we investigated whether claudin CPE receptors can be a target for tumor metastasis by using the claudin-4-targeting PSIF as a claudin-targeting agent.

Materials and Methods

Cell Culture. Mouse melanoma cell line B16-BL6 and mouse breast cancer cell line 4T1 were cultured in modified Eagle's medium supplemented with 10% fetal bovine serum (FBS) and Dulbecco's modified Eagle's medium (DMEM) containing 10% FBS and 10 mmol/ml HEPES, respectively. The cells were maintained in a 5% CO₂ atmosphere at 37°C.

Preparation of B16 Cells Stably Expressing Claudin-4. Mouse claudin-4 cDNA was subcloned into pDNA3.1 plasmid coding a neomycin resistance gene. The claudin-4 expression vector was transfected into B16 cells, and B16 cells stably expressing claudin-4 (CL4-B16 cells) were isolated by geneticin selection.

Immunoblot Analysis. Cells were lysed in lysis buffer [50 mM Tris (pH 7.4), 8.25 mg/ml NaCl, 1% NP-40, 2 mM SDS, and protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO)]. The cell lysates were subjected to SDS-polyacrylamide gel electrophoresis. The separated proteins were transferred onto a polyvinylidene difluoride membrane, followed by immunoblotting with anti-claudin-4 (Zymed Laboratories, South San Francisco, CA) or anti- β -actin Ab (Sigma-Aldrich). After incubation with a peroxidase-labeled secondary antibody (Millipore Bioscience Research Reagents, Temecula, CA), the immunoreactive band was visualized by chemiluminescence reagents (GE Healthcare, Little Chalfont, Buckinghamshire, UK).

Cell Proliferation Assay. B16 or CL4-B16-expressing cells (CL4-B16 cells) (2×10^4 cells) were seeded into a 24-well plate. At the indicated time points, the cells were stained with trypan blue, and the number of viable cells was counted by using a hemocytometer under a microscope.

In Vitro Metastasis Analysis. A cell culture insert with an 8- μ m pore size membrane (BD Biosciences Discovery Labware, Bedford,

MA) was used for the invasion assay. The upper surface of the chamber was coated with 50 μ l of 0.1 mg/ml Matrigel (BD Biosciences, San Jose, CA), and the lower chamber was filled with DMEM containing 10% FBS. Cells were cultured to approximately 80% confluence and serum-starved overnight (0.5% FBS). Then, cells (1×10^5 cells) suspended in DMEM with 0.5% FBS were placed into the upper chamber and incubated at 37°C for 24 h. After incubation, noninvasive cells were removed, and the membrane was stained with Diff-Quick reagent. The stained cells in five randomly selected fields were counted under a microscope.

Preparation of C-CPE-PSIF. The C-terminal fragment of CPE (C-CPE)-fused PSIF (C-CPE-PSIF) was prepared as described previously (Saeki et al., 2009). In brief, pET-C-CPE-PSIF was transfected into *Escherichia coli* BL21 (DE3) (Novagen, Darmstadt, Germany), and the production of C-CPE-PSIF was induced by the addition of 0.25 mM isopropyl-D-thiogalactopyranoside. The cells were harvested and then lysed in buffer A (10 mM Tris-HCl (pH 8.0), 400 mM NaCl, 5 mM MgCl₂, 0.1 mM phenylmethylsulfonyl fluoride, 1 mM 2-mercaptoethanol, and 10% glycerol). The lysates were centrifuged, and the resultant supernatant was applied to HiTrap Chelating HP (GE Healthcare). The proteins were eluted by imidazole in buffer A. The buffer was exchanged with phosphate-buffered saline (PBS) by using a PD-10 column (GE Healthcare), and the purified protein was stored at -80°C until use. Protein was quantified by using a BCA protein assay kit (Pierce Chemical, Rockford, IL) with BSA as a standard.

In Vitro Cytotoxic Analysis. In the cytotoxic assay, B16 and CL4-B16 cells were seeded onto a 96-well culture dish at 1×10^4 cells per well. After 24 h, the cells were treated with C-CPE-PSIF for 24 h at the indicated concentrations. The cytotoxicity was determined by a WST-8 kit, according to the manufacturer's instructions (Nacalai Tesque, Kyoto, Japan).

In Vivo Antitumor Activity. Female BALB/c mice (7–8 weeks old) and C57/BL6 mice (7–8 weeks old) were obtained from Shimizu Laboratory Supplies Co., Ltd. (Kyoto, Japan). The mice were housed in an environmentally controlled room at $23 \pm 1.5^\circ\text{C}$ with a 12-h light/dark cycle. The animal experiments were performed according to the guidelines of Osaka University.

For an experimental metastasis model, B16 or CL4-B16 cells (5×10^5 or 1×10^6 cells) in 100 μ l of PBS were injected intravenously into the tails of C57/BL6 mice. Then, mice received intravenously administered PBS or C-CPE-PSIF three times per week. Two weeks after the inoculation of the cells, the mice were sacrificed, and the number of lung metastasis colonies was counted under a microscope. For antitumor activity in B16 cells, 1×10^5 B16 or CL4-B16 cells were injected subcutaneously into the right flanks of C57BL/6 mice. Vehicle or C-CPE-PSIF was intravenously administered three times per week. Calipers were used to measure the minimal and maximal tumor diameters, and the tumor volume was calculated as $a \times b \times b/2$, where a represents the minimal tumor diameter, and b represents the maximal tumor diameter. The body weights of mice were also monitored.

For antitumor activity in 4T1 cells, 4T1 cells (1×10^6 cells) in 50 μ l of PBS were injected subcutaneously into the right flanks of BALB/c mice. PBS, C-CPE-PSIF, or adriamycin (ADR) was intravenously administered, and the tumor size and body weight of mice were monitored. Mice were sacrificed 35 days after tumor inoculation, and lung metastasis was evaluated by staining with India ink.

Statistical Analysis. Data were analyzed by using Dunnett's method. The statistical significance for all comparisons was set at $p < 0.05$.

Results

Preparation of Claudin-4-Expressing B16 BL6 Cells.

To investigate the effects of C-CPE-PSIF on tumor metastasis, we selected murine B16 cells, which have a high propensity

to metastasize to the lung (Saiki, 1997). Western blotting analysis revealed no expression of claudin-4 in B16 cells (Fig. 1A). B16 cells were not sensitive to C-CPE-PSIF (Fig. 2A). We transfected claudin-4 cDNA into B16 cells and established stable CL4-B16 cells (Fig. 1A). The proliferation rate was not affected by exogenously expressed claudin-4 (Fig. 1B). Metastasis has multiple processes, including motility and invasion (Steeg, 2006). To investigate the invasion of CL4-B16 cells, we performed a Boyden chamber migration assay. Cells were seeded onto the cell culture insert of Matrigel-coated membrane with an 8- μm pore size, and the cells that invaded the apical membrane and reached the basal membrane were counted. As shown in Fig. 1C, the invasion activity was increased 17-fold in CL4-B16 cells compared with that in parental B16 cells. Lung metastasis of CL4-B16 cells was observed when intravenously injected into mice; however, the number of lung metastasis colonies of CL4-B16 cells was smaller than that of the parental B16 cells (Fig. 1D). These findings indicate that CL4-B16 cells can be used as a metastasis model of claudin-4-expressing cancer cells. We discuss the elevation of migration activity and lower lung metastasis in CL4-B16 cells under *Discussion*.

Antitumor Activity of C-CPE-PSIF in CL4-B16 Cells.

Before *in vivo* experiments, we investigated the *in vitro* cytotoxicity of C-CPE-PSIF in CL4-B16 cells. As shown in Fig. 2A, C-CPE-PSIF showed dose-dependent cytotoxicity in CL4-B16 cells, decreasing their viability to 35% at 100 ng/ml. In contrast, parental B16 cells were not sensitive to C-CPE-PSIF even at 1 $\mu\text{g}/\text{ml}$, indicating that C-CPE-PSIF may target claudin-4. Claudin-4 is expressed in the intestines, liver, and kidney (Morita et al., 1999). To determine a safe dose of C-CPE-PSIF, we checked serum biochemical markers of liver (alanine aminotransferase) and kidney (blood urea nitrogen) injury in mice injected with C-CPE-PSIF. After intravenous administration of C-CPE-PSIF (5 $\mu\text{g}/\text{kg}$), the mice showed no signs of injury (data not shown). In the following *in vivo* experiments, the doses of C-CPE-PSIF were less than or equal to 5 $\mu\text{g}/\text{kg}$. B16 or CL4-B16 cells were intravenously injected into mice, and then C-CPE-PSIF was intravenously administered every 2 days. Two weeks after the tumor cell injection, the number of lung metastasis colonies was counted. As shown in Fig. 2B, C-CPE-PSIF treatment decreased the number of lung metastasis colonies from 39 \pm 17 to 10 \pm 4 at 5 $\mu\text{g}/\text{kg}$. In contrast, C-CPE-PSIF treatment did not affect the lung metastasis of B16 cells (Fig. 2B). C-CPE-PSIF suppressed the growth of CL4-B16 cells but not B16 cells inoculated into the right flank of mice (Fig. 2C). These data suggest that claudin-4 targeting may be a potent strategy for suppressing tumor metastasis and growth.

Suppression of the Primary Tumors and Metastasis of 4T1 Cells.

To clarify the potency of a claudin-4-targeting strategy, we investigated the effect of C-CPE-PSIF on a spontaneous metastasis model. 4T1 cells are murine cancer cells that spontaneously metastasize to the lung after being subcutaneously inoculated (Wong et al., 2002). We investigated whether C-CPE-PSIF suppresses the spontaneous lung metastasis of 4T1 cells. On day 33, the tumor volume was 1801.2 \pm 848.5 mm³ in the vehicle-treated group and 740.5 \pm 94.6 mm³ in the group treated with 5 $\mu\text{g}/\text{kg}$ C-CPE-PSIF (Fig. 3A). The number of lung metastasis colonies was decreased to 2 \pm 1 colonies at 5 $\mu\text{g}/\text{kg}$ C-CPE-PSIF (Fig. 3B). A dose of 2 $\mu\text{g}/\text{kg}$ C-CPE-PSIF did not suppress tumor growth




Fig. 1. Claudin-4-expressing B16 melanoma (CL4-B16) cells. **A**, preparation of CL4-B16 cells. Cell lysates from B16 and CL4-B16 cells were subjected to SDS-polyacrylamide gel electrophoresis, followed by Western blotting with claudin-4 and β -actin. β -Actin is a control for an endogenous protein. **B**, the effect of claudin-4 on cellular proliferation in B16 cells. B16 or CL4-B16 cells (2×10^4 cells) were seeded onto a 24-well plate. Then, the cell numbers were counted by trypan blue dye exclusion assay at the indicated periods. Data are shown as means \pm S.D. ($n = 4$). **C**, effect of claudin-4 on invasion in B16 cells. B16 or CL4-B16 cells (1×10^5 cells) were seeded into the upper well of the cell culture insert coated with Matrigel. After 24 h, the cells that invaded the bottom membrane of the insert were stained with DiffQuick reagent and counted under a microscope. Data are shown as means \pm S.D. ($n = 4$). *, significantly different from B16 cells ($p < 0.01$). **D**, lung metastasis of CL4-B16 cells. B16 or CL4-B16 cells (5×10^5 or 1×10^6 cells) were injected into the tail veins of mice. After 14 days, the mice were sacrificed, the lungs were fixed, and the colonies on the lung surface were counted. Data are shown as means \pm S.D. ($n = 5$). *, significantly different from B16 cells ($p < 0.01$).




Fig. 2. Antitumor activity of C-CPE-PSIF for CL4-B16 cells. A, cytotoxicity of C-CPE-PSIF in CL4-B16 cells. B16 cells (top) and CL4-B16 cells (bottom) were treated with PSIF or C-CPE-PSIF at the indicated concentrations for 24 h. Cell viability (%) was measured by a WST-8 kit, according to the manufacturer's instructions (Nacal Tesque). Data represent the mean \pm S.D. ($n = 3$). *, significantly different from the vehicle-treated group ($p < 0.05$). B, anti-metastatic activity of C-CPE-PSIF on lung metastasis of B16 (top) or CL4-B16 (bottom) cells. B16 or CL4-B16 cells (1×10^6 cells) were injected into the tail veins of mice on day 0, and vehicle or C-CPE-PSIF (2 or 5 $\mu\text{g}/\text{kg}$) was intravenously injected on days 0, 2, 4, 7, 9, 11, and 13. On day 14, the mice were sacrificed, their lungs were fixed, and the colonies on the lung surface were counted. Data are shown as means \pm S.D. ($n = 5$). *, significantly different from the vehicle-treated group ($p < 0.05$). C, antitumor activity of C-CPE-PSIF on CL4-B16 subcutaneously inoculated allograft. B16 (top) or CL4-B16 (bottom) cells (1×10^5 cells) were intradermally inoculated into the right flank of mice on day 0, and PBS or C-CPE-PSIF (2 or 5 $\mu\text{g}/\text{kg}$) was intravenously injected three times a week. Tumor volume was monitored. Each point is the mean \pm S.D. ($n = 5$). The data are representative of two independent experiments.

but did prevent lung metastasis. The circulating tumor cells might be more sensitive to C-CPE-PSIF than tumor cells in the solid tumor tissue. C-CPE-PSIF treatments did not cause a decrease in body weight (Fig. 3C), and there were no apparent biochemical side effects (Supplemental Fig. 1). ADR, which is frequently used in clinical chemotherapy, suppressed the tumor growth from 970.3 ± 278.4 to $458.6 \pm 51.4 \text{ mm}^3$ at 4 mg/kg (Fig. 3D). As shown in Fig. 3E, 4 mg/kg ADR decreased the number of lung metastasis colonies (24 ± 13 colonies in the vehicle-treated group; 6 ± 4 colonies in the ADR-treated group). However, the ADR-treated mice experienced a 26% loss of body weight, which is a sign of side effects (Fig. 3F). Thus, the antitumor activity of C-CPE-PSIF might

be more potent than that of ADR. These results indicate that claudin-4-targeting therapy might be a potent strategy for tumor therapy with a low level of side effects and a high level of antitumor activity.

Discussion

Most malignant tumors are derived from the epithelium, and metastasis is the major cause of death from cancers. In the present study, we found that systemic administration of a claudin-targeting molecule suppressed cancer metastasis, indicating that claudin targeting might be an effective therapy against cancer metastasis.




Fig. 3. Antitumor activity of C-CPE-PSIF for murine breast cancer 4T1 cells. 4T1 cells (1×10^5 cells) were intradermally inoculated into the right flanks of mice on day 0, and C-CPE-PSIF (A–C) or ADR (D–F) was intravenously injected three or two times a week at the indicated doses, respectively. Tumor volume (A and D) and body weight (B and E) were monitored. On day 35, the mice were sacrificed, their lungs were stained with India ink, and the number of spontaneous metastases was determined (C and F). Data are shown as means \pm S.D. ($n = 5$). *, significantly different from the vehicle-treated group ($p < 0.01$). The data are representative of two independent experiments.

Although the *in vitro* metastasis activity of CL4-B16 cells was higher than that of parental B16 cells, the *in vivo* lung metastasis of CL4-B16 cells was lower than that of B16 cells. As shown in Supplemental Fig. 2, claudin-4 increased the invasiveness and migration activity of B16 cells *in vitro* and decreased lung metastasis *in vivo*. A possible explanation for this discrepancy might be the experimental model, which evaluates a different stage of metastasis. The migration and invasion activity involved in the early stage of metastasis was investigated in the *in vitro* analysis, whereas extravasation and colonization to an organ involved in the late stage of metastasis was evaluated by the *in vivo* experiment. The altered expression of claudin-4 changed the metastasis of 4T1 cells to the heart and liver, suggesting that claudin affects organ-specific metastasis (Erin et al., 2009). Claudin-4 might suppress the lung metastasis of B16 cells.

Claudin is a structural and functional component of TJs (Furuse and Tsukita, 2006). What is the role of claudin in metastasis? Metastasis is composed of three steps: leaving the primary site, entering the blood flow, and invading the distant site. In the first step, the combination of claudin members in the TJ strands may be important. The claudin family contains at least 24 members. Claudin is believed to form homo- and hetero-type claudin strands, and the pattern

of the strands differs among tissues and determines the properties of TJ seals (Furuse and Tsukita, 2006). For example, rigid TJ seals were formed when claudin-11 or claudin-15 was exogenously expressed in Madin-Darby canine kidney cells, whereas the expression of claudin-11 or claudin-15 reduced the TJ integrity in LLC-PK1 cells by its dominant negative effects on TJ sealing (Van Itallie et al., 2003). Dominant negative effects of claudin-4 on the TJ barrier might contribute to an acceleration in the detachment of cancer cells from the primary tumor tissue. In the second and third steps of metastasis, cancer cells must move through the extracellular matrix at the primary site and the distant site. Cancer cells must degrade the extracellular matrix by the expression of matrix metalloproteinase and increase their motility. Claudin expression enhanced invasion with increased matrix metalloproteinase activity (Agarwal et al., 2005). There is a relationship between the levels of claudin-1/claudin-4 and the metastasis of human cancers, including hepatic, colonic, ovarian, and gastric cancers (Miwa et al., 2001; Agarwal et al., 2005; Resnick et al., 2005; Halder et al., 2008; Lee et al., 2008). The overexpression of claudin suppressed cancer metastasis in human pancreatic and gastric cancers (Michl et al., 2003; Mima et al., 2005; Ohtani et al., 2009). Claudin-4 suppressed or accelerated *in vitro* and *in*

AQ: D

AQ: E

vivo metastasis of human cancer cells (Agarwal et al., 2005; Ohtani et al., 2009). Cell-cell interaction through TJs regulates cell growth signaling (Matter et al., 2005). Taken together, these findings indicate that claudin family members might control several steps of cancer metastasis. The precise molecular mechanism and role of claudin in cancer metastasis remain to be determined.

Whether a claudin-4-targeting method causes severe side effects is critical for its clinical application in cancer therapy. Claudins play pivotal roles in TJ barrier and fence functions by maintaining cellular polarity in normal epithelium (Furuse and Tsukita, 2006). Claudins are believed to be more accessible in tumors than in normal epithelium. Claudins form TJ seals in lateral membranes between adjacent cells in normal epithelium, whereas claudins are exposed on the cell surface during tumorigenesis (Soler et al., 1999; Kominsky, 2006). Indeed, no local or systemic side effects have been observed after the intratumoral administration of CPE (Kominsky et al., 2007; Santin et al., 2007). Here, we also found that the systemic administration of C-CPE-PSIF causes no significant increase in biochemical markers (aspartate aminotransferase, alanine aminotransferase, and blood urea nitrogen) for toxicity at a therapeutic dose of 5 µg/kg (Supplemental Fig. 2). Thus, a claudin-targeting strategy might have weak side effects.

It is difficult to prepare recombinant claudin protein because of its hydrophobic property, and claudin has low antigenicity. Until recently, an antibody against the extracellular loop domain of claudin had never been successfully prepared, and C-CPE was the only known claudin binder. Recently, Romani et al. (2009) prepared a single-chain antibody fragment against claudin-3 by using phage display technology. They found that the antibody fragment binds to ovarian and uterine carcinoma cells in vitro. More importantly, a therapeutic monoclonal antibody against claudin-4 was developed. Suzuki et al. (2009) successfully prepared anti-claudin-4 antibody by immunizing claudin-4-expressing tumor cells into a mouse with autoimmune disease. The antibody mediates antibody-dependent cellular cytotoxicity and both in vitro and in vivo antitumor activity. Although the preparation of anti-claudin antibody may lead to a breakthrough in cancer therapy, the immunogenicity associated with immunotoxin clinical therapies is a future problem (Kreitman and Pastan, 2006). The C-terminal 30 amino acids are the minimum functional domain of C-CPE to bind to claudin-4 (Hanna et al., 1991). The C-terminal 30-amino-acid fragment was used to deliver a cytokine to claudin-4-expressing cells by genetic fusion (Yuan et al., 2009). Humanized antibody and the claudin-4-targeting peptide may be useful for cancer therapy in the near future.

In summary, this is the first report to indicate that systemic injection of a claudin-targeting molecule suppresses tumor growth and metastasis. Hematologic cells do not develop TJs; therefore, a claudin-targeting therapy may have no hematologic toxicity. We anticipate that claudin targeting will be a potent strategy for cancer therapy.

Acknowledgments

We thank members of our laboratory for useful comments and discussion and Drs. Y. Horiguchi (Osaka University, Osaka, Japan), S. Tsunoda (National Institute of Biomedical Innovation, Osaka, Japan), and M. Furuse (Kobe University, Hyogo, Japan) for providing C-CPE cDNA, PSIF cDNA, and claudin cDNA, respectively.

References

Agarwal R, D'Souza T, and Morin PJ (2005) Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. *Cancer Res* 65:7378-7385.

Dhawani P, Singh AB, Deane NG, No Y, Shioi SR, Schmidt C, Neff J, Washington MK, and Beachamp RD (2005) Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. *J Clin Invest* 115:1765-1776.

Erin N, Wang N, Xin P, Bui V, Weisz J, Barkan GA, Zhao W, Shearer D, and Clawson GA (2009) Altered gene expression in breast cancer liver metastases. *Int J Cancer* 124:1503-1516.

Furuse M and Tsukita S (2006) Claudins in occluding junctions of humans and flies. *Trends Cell Biol* 16:181-188.

Gupta GP and Massagué J (2006) Cancer metastasis: building a framework. *Cell* 127:679-695.

Halder SK, Rachakonda G, Deane NG, and Datta PK (2008) Smad7 induces hepatic metastasis in colorectal cancer. *Br J Cancer* 99:957-965.

Hanna PC, Mietzner TA, Schoolnik GK, and McClane BA (1991) Localization of the receptor-binding region of *Clostridium perfringens* enterotoxin using cloned toxin fragments and synthetic peptides. The 98 C-terminal amino acids define a functional binding region. *J Biol Chem* 266:11037-11043.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, and Thun MJ (2008) Cancer statistics, 2008. *CA Cancer J Clin* 58:71-96.

Kominsky SL (2006) Claudins: emerging targets for cancer therapy. *Expert Rev Mol Med* 6:1-10.

Kominsky SL, Tyler B, Sosnowski J, Brady K, Doucet M, Nell D, Smedley JG 3rd, McClane B, Brem H, and Sukumar S (2007) *Clostridium perfringens* enterotoxin as a novel targeted therapeutic for brain metastasis. *Cancer Res* 67:7977-7982.

Kominsky SL, Vail M, Korz D, Gabig TG, Weitzman SA, Argani P, and Sukumar S (2004) *Clostridium perfringens* enterotoxin elicits rapid and specific cytotoxicity of breast carcinomas mediated through tight junction proteins claudin 3 and 4. *Am J Pathol* 164:1627-1633.

Kreitman RJ and Pastan I (2006) Immunotoxins in the treatment of hematologic malignancies. *Curr Drug Targets* 7:1301-1311.

Lee LY, Wu CM, Wang CC, Yu JS, Liang Y, Huang KH, Lo CH, and Hwang TL (2008) Expression of matrix metalloproteinases MMP-2 and MMP-9 in gastric cancer and their relation to tumor invasion and expression. *Histol Histopathol* 23:515-521.

Martin TA and Jiang WG (2001) Tight junctions and their role in cancer metastasis. *Histol Histopathol* 16:1183-1195.

Matter K, Ajiya S, Tsapara A, and Balda MS (2005) Mammalian tight junctions in the regulation of epithelial differentiation and proliferation. *Curr Opin Cell Biol* 17:453-458.

McClane BA and Chakrabarti G (2004) New insights into the cytotoxic mechanisms of *Clostridium perfringens* enterotoxin. *Anaerobe* 10:107-114.

Michl P, Barth C, Buchholz M, Lerch MM, Rolke M, Holzmann KH, Menke A, Fensterer H, Giehl K, Lohr M, et al. (2003) Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. *Cancer Res* 63:6265-6271.

Michl P, Buchholz M, Rolke M, Kunsch S, Lohr M, McClane BA, Tsukita S, Leeder G, Adler G, and Lohr M (2001) Claudin-4, a new target for pancreatic cancer treatment using *Clostridium perfringens* enterotoxin. *Gastroenterology* 121:678-684.

Mima S, Tsutsumi S, Ushijima H, Takeda M, Fukuda I, Yokomizo K, Suzuki K, Sano K, Nakanishi T, Tomisato W, et al. (2005) Induction of claudin-4 by nonsteroidal anti-inflammatory drugs and its contribution to their chemopreventive effect. *Cancer Res* 65:1876-1876.

Mitic LL and Anderson JM (1998) Molecular architecture of tight junctions. *Annu Rev Physiol* 60:121-142.

Morin PJ (2005) Claudin proteins in human cancer: promising new targets for diagnosis and therapy. *Cancer Res* 65:9603-9606.

Morita K, Furuse M, Fujimoto K, and Tsukita S (1999) Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. *Proc Natl Acad Sci USA* 96:511-516.

Mullin JM (1997) Potential interplay between luminal growth factors and increased tight junction permeability in epithelial carcinogenesis. *J Exp Zool* 279:484-489.

Ohtani S, Terashima M, Satoh J, Soeta N, Saze Z, Kashimura S, Ohnaka F, Hoshino Y, Kogure M, and Gotoh M (2009) Expression of tight junction-associated proteins in human gastric cancer: down-regulation of claudin-4 correlates with tumor aggressiveness and survival. *Gastric Cancer* 12:43-51.

Reisnick MB, Konkin T, Routhier J, Sabo E, and Priolo VE (2005) Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. *Mod Pathol* 18:511-518.

Romani C, Comper F, Bandiera E, Ravaggi A, Bignotti E, Tassi RA, Pecorelli S, and Santin AD (2009) Development and characterization of human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. *Am J Obstet Gynecol* 201:70.e71-e79.

Saeki R, Kondoh M, Kakutani H, Tsunoda S, Mochizuki Y, Hamakubo T, Teutsumi Y, Horiguchi Y, and Yagi K (2009) A novel tumor-targeted therapy using a claudin-4-targeting molecule. *Mol Pharmacol* 76:915-926.

Saiki I (1997) Cell adhesion molecules and cancer metastasis. *Jpn J Pharmacol* 75:215-242.

Santin AD, Bellone S, Marizoni M, Palmieri M, Siegel ER, McKenney JK, Hennings L, Comper F, Bandiera E, and Pecorelli S (2007) Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using *Clostridium perfringens* enterotoxin (CPE). *Cancer* 109:1312-1322.

Santin AD, Cavé S, Bellone S, Palmieri M, Siegel ER, Thomas M, Roman JJ, Burnett A, Cannon MD, and Pecorelli S (2005) Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of *Clostridium perfringens* enterotoxin. *Cancer Res* 65:4334-4342.

Soler AP, Miller RD, Lavaglini KV, Carp NZ, Klurfeld DM, and Mullin JM (1999) Increased tight junction permeability is associated with the development of colon cancer. *Carcinogenesis* 20:1425-1431.

- Y: G Sonoda N, Furuse M, Sasaki H, Yonemura S, Katahira J, Horiguchi Y, and Tsukita S (1999) *Clostridium perfringens* enterotoxin fragment removes specific claudins from tight junction strands: Evidence for direct involvement of claudins in tight junction barrier. *J Cell Biol* **147**:195–204.
- Stachelin LA (1975) Further observations on the fine structure of freeze-cleaved tight junctions. *J Cell Sci* **13**:763–786.
- Steeg PS (2006) Tumor metastasis: mechanistic insights and clinical challenges. *Nat Med* **12**:895–904.
- Suzuki M, Kato-Nakano M, Kawamoto S, Furuya A, Abe Y, Misaka H, Kimoto N, Nakamura K, Ohta S, and Ando H (2009) Therapeutic antitumor efficacy of monoclonal antibody against claudin-4 for pancreatic and ovarian cancers. *Cancer Sci* **100**:1623–1630.
- Van Itallie CM, Fanning AS, and Anderson JM (2003) Reversal of charge selectivity in cation or anion-selective epithelial lines by expression of different claudins. *Am J Physiol Renal Physiol* **285**:F1078–F1084.
- Vermeer PD, Einwalter LA, Moninger TO, Rokhlina T, Kern JA, Zabner J, and Welsh MJ (2003) Segregation of receptor and ligand regulates activation of epithelial growth factor receptor. *Nature* **422**:322–326.
- Wodarz A and Nathke I (2007) Cell polarity in development and cancer. *Nat Cell Biol* **9**:1016–1024.
- Wong CW, Song C, Grimes MM, Fu W, Dewhurst MW, Muschel RJ, and Al-Mehdi AB (2002) Intravascular location of breast cancer cells after spontaneous metastasis to the lung. *Am J Pathol* **161**:749–753.
- Yuan X, Lin X, Manorek G, Kanatani I, Cheung LH, Rosenblum MG, and Howell SB (2009) Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors. *Mol Cancer Ther* **8**:1906–1915.

Address correspondence to: Dr. Masuo Kondoh, Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871, Japan. E-mail: masuo@phs.osaka-u.ac.jp

AQ: H

NOT FOR



DISTRIBUTION